Market Newsdesk

SAN FRANCISCO, Nov. 12, 2020 (GLOBE NEWSWIRE) — Nitrome Biosciences (Nitrome), a privately-held biopharmaceutical company developing a platform around its newly discovered class of enzymes to target Parkinson’s disease and many other age-related and inflammatory disorders, today announced the formation of its Scientific Advisory Board (SAB). Industry drug discovery and development veteran, James Summers, Ph.D., has been appointed chairperson of the SAB.

“As we embark on newly discovered science in aging and inflammation biology, we look forward to thought leadership and close collaboration with the scientific leaders appointed to our SAB ,” said Irene Griswold-Prenner, Ph.D., founder, chief executive officer and chief scientific officer of Nitrome. “We are thrilled that this esteemed group of scientists has agreed to support our vision of advancing Nitrome science to patients. We look forward to Jim’s leadership and guidance as our SAB chair as we translate Nitrome science into important therapeutics.”

Dr. Summers added, “Dr. Griswold-Prenner’s discovery of an entirely new class of enzymes has the potential to transform the treatment of Parkinson’s disease and other age-related disorders. I am honored to be a part of this innovative scientific team. I very much look forward to working with the other SAB members and the company’s superb research and development team to guide Nitrome discoveries into clinical development.”

The SAB will be comprised of the following members:

SAB Chair
person
– James Summers, Ph.D.
, former Vice President, Neuroscience Research, Abb
V
ie

James B. Summers, Ph.D., has more than three decades of drug discovery and pharmaceutical research management experience spanning multiple therapeutic areas. Under his leadership at Abbott Laboratories and at AbbVie, teams have advanced more than 20 compounds into clinical development. He established new research sites in Cambridge, Massachusetts and Shanghai, China, was an architect of several strategies that defined the future direction of global research organizations, and championed multiple successful licensing deals, biotech collaborations and venture investments. Dr. Summers has held various senior R&D leadership positions where he led efforts focused on the discovery of new drugs for the treatment of Alzheimer’s and Parkinson’s diseases, pain, and psychiatric disorders. Most recently, he was vice president of neuroscience research at AbbVie. Dr. Summers also served as divisional vice president, advanced technology with Abbott where he was responsible for an organization engaged in a broad range of technologies and core services that enabled and accelerated drug discovery research across all of Abbott’s therapeutic areas and sites. Dr. Summers holds a BS, summa cum laude, in chemistry from Denison University and a Ph.D. in organic chemistry from Harvard University.

Harry Ischiropoulos, Ph.D.,
Children’s Hospital of Philadelphia

Harry Ischiropoulos, Ph.D., is the Gisela and Dennis Alter research professor of Pediatrics and Systems Pharmacology and Translational Therapeutics at the Children’s Hospital of Philadelphia Research Institute and the Perelman School of Medicine at the University of Pennsylvania. His laboratory investigates the biological chemistry and signaling pathways of nitric oxide in the cardiovascular and neuronal systems using mass spectroscopy-based technologies. Dr. Ischiropoulos has authored 195 publications and is the recipient of several professional awards including an Established Investigator award from the American Heart Association. He served on several NIH review panels and advisory committees. He was the president for the Society for Free Radical Biology and Medicine and served on the board of directors for the Federation of American Societies for Experimental Biology. He was an editor for the journal Free Radical Biology and Medicine and chaired the Gordon Research Conferences on Oxygen Radicals (2014) and on Nitric Oxide (2015). Dr. Ischiropoulos received a BS in chemistry from Wagner College, an MS in pathology and a Ph.D. in experimental pathology from New York Medical College.

Regis
B.
Kelly, Ph.D.
, Executive Director QB3

Regis B. Kelly, Ph.D., is the executive director of QB3, one of the four Governor Gray Davis Institutes for Science and Innovation. As executive director, Dr. Kelly helped launch two QB3-associated companies, QB3@953 now MBC Biolabs, a life sciences startup incubator, and Mission Bay Capital, a venture fund. As a result of his experiences, Dr. Kelly was appointed as senior advisor on innovation and entrepreneurship to the president of the University of California, Janet Napolitano. Prior to joining QB3 in 2004, Dr. Kelly served as executive vice-chancellor at UCSF and chairman of the department of biochemistry and biophysics. Dr. Kelly received an undergraduate degree in physics from the University of Edinburgh in Scotland and a Ph.D. in biophysics from the California Institute of Technology. Following a post-doctoral fellowship at Stanford, Dr. Kelly was an instructor in the department of neurobiology at Harvard.

Stevan
W
Djuric, Ph.D.
, former Head of Global Medicinal Chemistry, Abb
V
ie

Stevan W Djuric, Ph.D., was, until retirement in February 2019, head of the global AbbVie medicinal chemistry leadership team at AbbVie and Vice President of the Discovery Chemistry and Technology organization. The technology organization’s efforts were focused on initiatives in the areas of high throughput synthesis and purification, hit-to-lead chemistry, chemical biology and new MS-based analytical technologies. In 2015 he was named a Distinguished Research Fellow. During his tenure at Abbott and AbbVie Laboratories, Dr. Djuric was a project leader for groups in the immunoscience, metabolic disease, and anti-infective areas. Several of these programs advanced compounds into clinical development and to the market including Abbott’s proprietary rapamycin analog, Zotarolimus, currently licensed to Medtronics for use on their vascular stents, marketed in the United States and Europe. Dr. Djuric has over 180 scientific publications, presentations and patents/applications pending. He has also given over 40 invited lectures at universities and national meetings. He is a member of several Editorial Advisory Boards including the Journal of Medicinal Chemistry and is an Associate Editor of ACS Medicinal Chemistry Letters. In addition, he holds an Adjunct Professorship in the Department of Medicinal Chemistry at the University of Kansas and one at High Point University in North Carolina.

Zach W. Hall, Ph
.
D
.
, Neurobiologist, former
President of CIRM

Zach W. Hall, Ph.D., is a retired neuroscientist whose laboratory studied the molecular structure and development of the neuromuscular junction. He received his Ph.D. with Ed Kravitz at Harvard University in 1966. Following two years of post-doctoral work in the Department of Biochemistry at Stanford, Hall returned to Harvard to join the new Department of Neurobiology as an Assistant Professor. In 1976 he moved to UCSF where he started the Neuroscience Graduate Program. From 1994-97 he was director of the National Institute of Neurological Disorders and Stroke before returning to UCSF as Executive Vice Chancellor, with responsibility for developing the campus at Mission Bay. He then held a series of administrative positions, including the CEO of EnVivo Pharmaceuticals and later Associate Dean for Research at the Keck School of Medicine at the University of Southern California. His last position was as the first president of the California Institute of Regenerative Medicine, a new state agency to fund stem cell research in California. Hall was one of the founding editors of Neuron, and is the author and editor of a textbook, An Introduction to Molecular Neurobiology. He has received a number of honors, including the Purkynje Medal from the Czech Academy of Sciences. Hall, who now lives in Wilson, WY, currently serves as an advisor and board member for Target ALS, a non-profit organization devoted to speeding the development of therapies for ALS by promoting collaboration between industry and academia.

Kalpana Merchant, Ph.D.
,
Neuroscientist, former Eli Lilly, Pharmacia

Kalpana Merchant, Ph.D., an expert in neurobiology of chronic neurodegenerative and psychiatric disorders, has nearly 25 years of experience in drug discovery and development, with a special emphasis on translational approaches. She retired from Eli Lilly in 2014 where she was the chief scientific officer for tailored therapeutics-neuroscience, where her team was accountable for personalized therapies and associated biomarkers for the neuroscience portfolio. Dr. Merchant joined Eli Lilly in 2003 after contributing to neuroscience drug discovery at Pharmacia Corp. for over 10 years. Since 2014, she has held chief executive/scientific officer roles at Chaperone Therapeutics and Vincere Biosciences. She serves as an advisor to the Michael J Fox Foundation for Parkinson’s research, several NIH working groups and a number of start-up pharmaceutical companies. She is an Adjunct Professor of Neurology at Northwestern University. Dr. Merchant received her Ph.D. in neuropharmacology from University of Utah in 1989. Following a postdoctoral fellowship at University of Washington, she remained at the institute as assistant professor of psychiatry, later transitioning to the pharmaceutical industry.

About Nitrome Biosciences

Nitrome Biosciences is a platform company developing drugs against a newly identified class of enzymes which play a harmful role in a variety of age and inflammation dependent diseases. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases including Parkinson’s, Nitrome’s lead indication. The company also aims to expand its proprietary platform to include other diseases, such as other neurodegenerative diseases, macular degeneration, heart disease and cancer. Nitrome has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). For more information, please visit the company’s website at www.nitromebiosciences.com.

Investor Relations Contact:

Alexandra Santos
Wheelhouse Life Science Advisors
[email protected]

Media Contact:

Aljanae Reynolds
Wheelhouse Life Science Advisors
[email protected] 

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — via InvestorWire — The Virtual Summer Summit will take place on November 16th-18th, connecting 77 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below along with webcasting links to view presentations.

About the Investor Summit

The Investor Summit Group (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Having produced successful conferences over the past 5 years, the upcoming event will be the 3rd virtual edition added to our growing portfolio where hundreds of high-quality meetings between executives and investors will take place over 3 days. We pride ourselves on building community and providing a platform for our industry and look forward to launching new features at the upcoming Fall Summit such as virtual networking, panels and a stock pitch competition to promote endless connections in a virtual format.

To register for the upcoming Investor Summit, visit our website at www.investorsummitgroup.com

General Inquiries:

Brittney Blocker
Interim COO
[email protected] 

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com 
310.299.1717 Office
[email protected] 

Rockville, Md., Nov. 12, 2020 (GLOBE NEWSWIRE) — With Medicaid and the Children’s Health Insurance Program (CHIP) providing health insurance to 20 percent of Americans—including low-income individuals and families, pregnant women and children, and people with disabilities—it’s important that the effectiveness of these programs is optimized. Abt’s extensive work with vulnerable populations and our considerable experience working with Medicaid and CHIP have resulted in a position on  five-year contract to support the Medicaid and CHIP Payment and Access Commission (MACPAC).

MACPAC’s professional staff of economists, analysts, and health policy experts conduct research and analysis and present their findings to MACPAC’s Commissioners, who develop recommendations that are summarized in two annual reports to Congress. Abt will provide critical data collection and evaluation to inform MACPAC’s analyses.

The position on the indefinite delivery, indefinite quantity contract gives Abt the opportunity to bid on task orders that may include:

• Conducting environmental scans/information syntheses;
• Developing and framing policy options;
• Conducting limited surveys and focus groups;
• Analyzing survey and administrative data.

“Abt’s multidisciplinary staff understand the spectrum of interlocking health and social needs that affect the diverse range of Medicaid and CHIP populations,” said Abt’s Dr. Christopher Spera, division vice president, Health and Environment. “Through this contract, MACPAC will have access to researchers who combine this insight with deep experience providing evaluation and technical assistance to state Medicaid and CHIP programs and their partner agencies.”

###

About Abt Associates

Abt Associates is a global consulting and research firm that uses data and bold thinking to improve the quality of people’s lives. From combatting infectious disease and conducting rigorous program evaluations, to ensuring safe drinking water and promoting access to affordable housing —and more—we partner with clients and communities to tackle their most complex challenges. 

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:  (1) Aurora had significantly overpaid for previous acquisitions and experienced degradation in certain assets, including its production facilities and inventory; (2) the Company’s purported “business transformation plan” and cost reset failed to mitigate the foregoing issues; (3) accordingly, it was foreseeable that the Company would record significant goodwill and asset impairment charges; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than December 1, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for BioMarin Pharmaceutical Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration (“FDA”) would not approve the Biologics License Application (“BLA”) for valoctocogene roxaparvovec without additional data; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than November 24, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Fluidigm Corporation (NASDAQ: FLDM) from February 7, 2019 through November 5, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Fluidigm Corporation investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Fluidigm was experiencing longer sales cycles; (2) as a result, Fluidigm’s revenue was reasonably likely to decline; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

——————————-

Contact:
Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1410
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
[email protected]

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) from December 7, 2017 through August 21, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Odonate Therapeutics, Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) tesetaxel was not as safe or well-tolerated as the Company had led investors to believe; (2) consequently, tesetaxel’s commercial viability as a cancer treatment was overstated; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than November 16, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
——————————-

Contact:  
Vik Pawar, Esq.  
Pawar Law Group  
20 Vesey Street, Suite 1410  
New York, NY 10007  
Tel: (917) 261-2277  
Fax: (212) 571-0938  
[email protected]  

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality (AR) for eCommerce, AR learning applications, and AR-enhanced video conferencing and virtual experiences, reported record results for its third quarter ended September 30, 2020. All figures are prepared in accordance with International Financial Reporting Standards (IFRS) unless otherwise indicated.

Q
3
2020
Financial
highlights:

• Total Bookings $6.7 million +327% growth over Q3 2019
• Record revenue grows 200% to $4.7 million
• Record backlog of $2 million
• Gross Profit grows 344% to $3.0 million with a 63% margin
• Working Capital of $13.6 million
• Full report has been filed and is available on SEDAR 

Live Q3 earnings call will be after the close today at 4:30pm

• Bridge Name: NexTech AR Solutions
• Conference ID: 597-9019
• Dial in: +1 (435) 777-2200
• Toll-Free + 1 (800) 309-2350

Other Q3 Highlights:

• Filed to up list its stock to NASDAQ Capital Market July 2^nd
• Hired Eugen Winschel 18-year SAP Executive as new COO 
• Doubled the size of the company to 140 in Q3 from just 70 in Q2 – to continue to meet the rapid ramp up in demand and increase the company’s technological capabilities
• Company became approved Microsoft partner
• Launched new distribution deals with well-known consumer brands including Dyson, Philips Norelco, MR. Coffee, VitaMix, Breviel and Cusinart
• Landed $250,000 edTech AR contract with Ryerson University 
• Appointed Ori Inbar to its Board of Directors, a recognized AR expert, having been involved in the industry for over a decade as both a startup entrepreneur and a venture capital investor through SuperVentures
• Acquired the assets of Next Level Ninjas for $720,000 cash consideration
• Launches “Screen AR” A New Augmented Reality Immersive Video Conferencing Software to Accelerate Business Opportunities
• Began building Collaborative Video Conferencing Capabilities to rival Zoom and address Telemedicine and Edtech Markets

NexTech attributes this massive growth to new customer acquisitions and the expansion of services for existing customers as the demand for AR and remote work solutions intensified. 

The company is continuing to experience a rapid rise in demand for all its services. However, demand is especially high for its AR Solutions which include WebAR, AR ads, ScreenAR, Human holograms as well as custom AR solutions. Demand for the company’s AR labs for education is growing at 200% /month while every virtual event the company does has multiple AR experiences. To meet this growing demand the company is currently hiring dozens of AR/VR, Unity, and 3D modeling experts.

Evan Gappelberg, CEO of NexTech comments, “NexTech’s third quarter growth was fueled by a combination of extraordinarily strong demand across all our businesses that we operate, not just one and we see that continuing into Q4. We are unique in that we are diversified with four fast growing businesses which all have a red thread of augmented reality connecting them, creating a major product differentiation and competitive advantage. He continues, “We are uniquely positioned with our augmented reality, eCommerce and InfernoAR video conferencing and virtual experience business units to thrive in this new economy being led by a digital transformation across technology. There has never been more business opportunity in our lifetime for augmented reality, virtual learning, virtual conferences, or virtual events and eCommerce, and we see strong business trends continuing in Q4 and beyond.”

NexTech AR Solutions Corp.
Condensed Consolidated Interim Statements of Financial Position
(Unaudited – Expressed in Canadian dollars)

NexTech AR Solutions Corp.
Condensed Consolidated Interim Statement of Comprehensive Loss
For the three and nine months ended September 30, 2020 and 2019
(Unaudited – Expressed in Canadian dollars)

NexTech AR Solutions Corp.
Condensed Consolidated Interim Statements of Changes in Shareholders’ Equity
For the nine months ended September 30, 2020 and 2019
(Unaudited – Expressed in Canadian dollars)

NexTech AR Solutions Corp.
Condensed Consolidated Interim Statement of Cash Flows
For the three and nine months ended September 30, 2020 and 2019
(Unaudited – Expressed in Canadian dollars)

(Above excerpts from the condensed consolidated interim financial statements should be read in conjunction with the financial statement notes).

Non-IFRS Measures

This News Release makes reference to certain non-IFRS measures such as “Total Bookings” and “Backlog”. These non-IFRS measures are not recognized, defined, or standardized measures under IFRS. Our definition of Total Bookings and Backlog will likely differ from that used by other companies and therefore comparability may be limited.

Total Bookings and Backlog should not be considered a substitute for or in isolation from measures prepared in accordance with IFRS. These non-IFRS measures should be read in conjunction with our condensed consolidated interim financial statements and the related notes thereto as at and for the three and nine months ended September 30, 2020. Readers should not place undue reliance on non-IFRS measures and should instead view them in conjunction with the most comparable IFRS financial measures. See the reconciliations to these IFRS measures below:

In accordance with the company’s stock option plan the company has issued 200,000, 3-year options priced at $7.70CDN and pursuant to a consulting agreement with Felix Ritscher Head of IT and Security previously announced on November 6^th, 2020, 4,100 common shares were also issued with a 4-month restriction.

About NexTech AR

NexTech is one of the leaders in the rapidly growing Augmented Reality market estimated to grow from USD $10.7B in 2019 and projected to reach USD $72.7B by 2024 according to Markets & Markets Research; it is expected to grow at a CAGR of 46.6% from 2019 to 2024.

The company is pursuing four verticals:

InfernoAR:
An advanced Augmented Reality and Video Learning Experience Platform for Events, is a SaaS video platform that integrates Interactive Video, Artificial Intelligence and Augmented Reality in one secure platform to allow enterprises the ability to create the world’s most engaging virtual event management and learning experiences. Automated closed captions and translations to over 64 languages. According to Grandview Research the global virtual events market in 2020 is $90B and expected to reach more than $400B by 2027, growing at a 23% CAGR. With NexTech’s InfernoAR platform having augmented reality, AI, end-to-end encryption and built in language translation for 64 languages, the company is well positioned to rapidly take market share as the growth accelerates globally.

ARitize™ For eCommerce:
The company launched its SaaS platform for webAR in eCommerce early in 2019. NexTech has a ​‘full funnel’ end-to-end eCommerce solution for the AR industry including its Aritize360 app for 3D product capture, 3D/AR ads, its ARitize white label app it’s ‘Try it On’ technology for online apparel, 3D and 360-degree product views, and ‘one click buy’.

ARitize™ 3D/AR Advertising Platform:
Launched in Q1 2020 the ad platform will be the industry’s first end-to-end solution whereby the company will leverage its 3D asset creation into 3D/AR ads. In 2019, according to IDC, global advertising spend will be about $725 billion.

ARitize™ Hollywood Studios
: The studio is in development producing immersive content using 360 video, and augmented reality as the primary display platform.

To learn more, please follow us on Twitter, YouTube, Instagram, LinkedIn, and Facebook, or visit our website: https://www.nextechar.com.

On behalf of the Board of NexTech AR Solutions Corp.

“Evan Gappelberg”
CEO and Director

For further information, please contact:

Evan Gappelberg
Chief Executive Officer
[email protected]   

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be”, “looking forward” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the Company increasing investors awareness are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of NexTech to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. NexTech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

PALM BEACH, FL, Nov. 12, 2020 (GLOBE NEWSWIRE) — Evolution in business occurs when an entrepreneur takes what has been and makes it better.

Fifteen years ago, Mitch Gould, a veteran retail professional, observed foreign health and wellness companies flailing and failing when entering the U.S. market.

“Companies exported their innovative products to the U.S. but failed because they didn’t understand our business culture and couldn’t keep expenses down,” said Gould, CEO and founder of Nutritional Products International. “They had expenses that continued to increase as they moved closer to selling their products.”

An international company exporting a brand to America had to rent office and warehouse space, hire sales and support staff, and either work with an outside marketing agency or develop an in-house staff to promote its brand.

“Before these companies made one sale, they had eaten away at their profit margin,” he said.

Gould said he knew there had to be a better way for new brands to reach retail outlets.

“I realized these companies needed an American partner who already had an office, warehouse space, a sales team, and marketing staff,” Gould said. “I created NPI to offer the services international brands needed to open up for business in the U.S.”

The Boca Raton-based NPI works with international health and wellness companies with brands they want to introduce to American consumers. The “Evolution of Distribution” process covers all aspects of successfully entering the U.S. market:

• Speed to Market/Sales Velocity
• Procurement of Purchase Orders
• Marketing and Promotion of Brand to Consumers and Retailers
• FDA Label Compliance Review
• Trademarking/Brand Protection
• Claims and Regulatory Review
• Warehousing
• National Network of Power Brokers
• Product Line Evaluation

“‘Evolution of Distribution’ is our proprietary system,” Gould said. “I have not seen another company in America that offers all the expertise and services that NPI provides its clients. We are unique.”

Gould has surrounded himself with leading retail professionals.

Jeff Fernandez, a former buyer from Amazon and Walmart, is NPI’s president, and Kenneth E. Collins, who worked as a director of sales for Glanbia Performance Nutrition, the world’s largest sports nutrition company, is the new executive vice president.

“Ken and I have a lot of contacts with retail buyers for large and small chains throughout the U.S.,” Fernandez said.

Collins, who was just hired, said he is looking forward to working with Gould and Fernandez.

“We have a lot of retail experience,” Collins said. “We bring a lot of knowledge, expertise, and success to our clients.”

For more information, visit Nutritional Products International online.

MORE ON NPI AND ITS FOUNDER

NPI is a privately-held company specializing in the retail distribution of nutraceuticals, dietary supplements, functional beverages, and skincare products. NPI offers a unique, proven approach for product manufacturers worldwide seeking to launch or expand their products’ distribution in the U.S. retail market.

Mitch Gould, the founder of NPI, is a third-generation retail distribution and manufacturing professional. Gould developed the “Evolution of Distribution” platform, which provides domestic and international product manufacturers with the sales, marketing, and product distribution expertise required to succeed in the world’s largest market — the United States. Gould, known as a global marketing guru, also has represented icons from the sports and entertainment worlds such as Steven Seagal, Hulk Hogan, Ronnie Coleman, Roberto Clemente Jr., Chuck Liddell, and Wayne Gretzky.

Attachment

• Mitch NPI Evolution of Distribution